Blood Res.  2021 Sep;56(3):129-133. 10.5045/br.2021.2021126.

Platelet count as an important prognostic factor for vaccine-induced immune thrombotic thrombocytopenia

• Bang SM
• Na SH
• Kim JH
• Kim SR
• Kim SR
• Jang S

• KMID: 2520581
• DOI: http://doi.org/10.5045/br.2021.2021126

Abstract

No abstract available

Figure

• 

  Fig. 1 Comparison of the distribution of the initial (A) and nadir (B) platelet counts between patients with favorable outcomes and those with unfavorable outcomes.

• 

  Fig. 2 Receiver operating characteristic curve to predict the prognosis of vaccine-induced immune thrombotic thrombocytopenia (VITT) with the nadir platelet count.

Reference

1. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. 2021; Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 384:2092–101. DOI: 10.1056/NEJMoa2104840. PMID: 33835769. PMCID: PMC8095372.

2. Muir KL, Kallam A, Koepsell SA, Gundabolu K. 2021; Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 384:1964–5. DOI: 10.1056/NEJMc2105869. PMID: 33852795. PMCID: PMC8063883.

3. Korea Disease Control and Prevention Agency (KDCA). 2021. The current status of Cov-19 vaccination. KDCA;Cheongju, Korea: at http://kdca.go.kr/board/board.es?mid=a20501010000&bid=0015&list_no=713731&cg_code=&act=view&nPage=1. Accessed on June 22, 2021.

4. Schultz NH, Sørvoll IH, Michelsen AE, et al. 2021; Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 384:2124–30. DOI: 10.1056/NEJMoa2104882. PMID: 33835768. PMCID: PMC8112568.

5. Scully M, Singh D, Lown R, et al. 2021; Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 384:2202–11. DOI: 10.1056/NEJMoa2105385. PMID: 33861525. PMCID: PMC8112532.

6. Bourguignon A, Arnold DM, Warkentin TE, et al. 2021; Adjunct Immune globulin for vaccine-induced thrombotic thrombo-cytopenia. N Engl J Med. [Epub ahead of print]. DOI: 10.1056/NEJMoa2107051. PMID: 34107198. PMCID: PMC8362588.

7. Korea Disease Control and Prevention Agency (KDCA). 2021. Public Health Weekly Report Vol. 14, No. 17, 2021. KDCA;Cheongju, Korea: at https://kdca.go.kr/board/board.es?mid=a20602010000&bid=0034&list_no=713111&act=view. Accessed on June 9, 2021.

8. Bourguignon A, Arnold DM, Warkentin TE, et al. 2021. The diagnosis and treatment guidelines for thrombosis with thrombocytopenia syndrome after Cov-19 vaccination. Korean Disease Control and Prevention Agency;Cheongju, Korea: at https://ncv.kdca.go.kr/board.es?mid=a12101000000&bid=0031#content. Accessed June 22, 2021.

9. Bourguignon A, Arnold DM, Warkentin TE, et al. 2021. Coronavirus vaccine - weekly summary of Yellow Card reporting. Medicines and Healthcare Products Regulatory Agency;London, UK: at https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting. Accessed June 3, 2021.

10. Bourguignon A, Arnold DM, Warkentin TE, et al. 2021. Selected adverse events reported after COVID-19 vaccination. Centers for Disease Control and Prevention;Atlanta, GA: at https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html. Accesed May 27, 2021.

11. Nazy I, Sachs UJ, Arnold DM, et al. 2021; Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost. 19:1585–8. DOI: 10.1111/jth.15341. PMID: 34018298. PMCID: PMC8250233.